Systematic Review of Effectiveness and Safety of Paclitaxel Combined with Carboplatin Synchronized with Radiotherapy and Chemotherapy in the Treatment of Cervical Cancer
返回论文页
|更新时间:2022-08-15
|
Systematic Review of Effectiveness and Safety of Paclitaxel Combined with Carboplatin Synchronized with Radiotherapy and Chemotherapy in the Treatment of Cervical Cancer
WEN Jianxia, YANG Tao, WANG Jian, et al. Systematic Review of Effectiveness and Safety of Paclitaxel Combined with Carboplatin Synchronized with Radiotherapy and Chemotherapy in the Treatment of Cervical Cancer. [J]. 20(1):14-22(2020)
WEN Jianxia, YANG Tao, WANG Jian, et al. Systematic Review of Effectiveness and Safety of Paclitaxel Combined with Carboplatin Synchronized with Radiotherapy and Chemotherapy in the Treatment of Cervical Cancer. [J]. 20(1):14-22(2020) DOI: 10.14009/j.issn.1672-2124.2020.01.004.
Systematic Review of Effectiveness and Safety of Paclitaxel Combined with Carboplatin Synchronized with Radiotherapy and Chemotherapy in the Treatment of Cervical Cancer
OBJECTIVE: To systematically evaluate the efficacy and safety of paclitaxel combined with carboplatin synchronized with radiotherapy and chemotherapy in the treatment of cervical cancer. METHODS: Chinese and English database were retrieved to collect the randomized controlled trial of paclitaxel combined with carboplatin synchronized with radiotherapy and chemotherapy in the treatment of cervical cancer( the control group was treated with radiotherapy alone
while the observation group received paclitaxel combined with carboplatin synchronized with radiotherapy and chemotherapy). The retrieve time was from the establishment of the database to Jun. 2019. Data were extracted according to the Cochrane Collaboration Network Quality Evaluation Standards
the methodological quality of the included literature was assessed
and RevMan 5. 3 software was used to conduct on the outcome indicators( Meta analysis). RESULTS: Totally 17 literature were collected
including 1 609 patients. The results of meta-analysis showed that the short-term and long-term efficacy of the observation group was significantly higher than that of the control group
with statistically significant differences( P<0. 05). There was no significant difference in the incidence of adverse drug reactions between two groups( P > 0. 05). Cervical cancer detection markers such as squamous epithelial cell carcinoma antigen( SCCAg) and cytokeratin 19 fragment antigen( CYFRA21-1) in the observation group were significantly lower than those in the control group
and the differences were statistically significant( P <0. 05). The asymmetry between left and right funnel diagrams suggested that there was a certain publication bias in the included lioteratyre. CONCLUSIONS: The clinical efficacy of paclitaxel combined with carboplatin synchronized with radiotherapy and chemotherapy in the treatment of cervical cancer is significantly better than that of radiotherapy alone
which can improve the disease control rate
improve the quality of life of patients
and reduce gastrointestinal reactions
bone marrow suppression
radiation colitis
radiation cystitis and other adverse drug reactions. Due to the low quality of the randomized controlled trials included in this study
more rationally designed
large-sample
multicenter randomized controlled trials need to be carried out to verify its clinical effectiveness and safety
so as to provide safe and effective guidance for paclitaxel combined with carboplatin synchronized with radiotherapy and chemotherapy in the treatment of cervical cancer.